Increase in Net Income
Net income for Q3 2025 was $1.12 per diluted share, up from $0.74 per diluted share in Q3 2024, driven by unrealized gains on preferred stock and stock warrant investments.
Book Value Increase
Book value per share increased by 8% from Q2 2025 to $18.79 per diluted share, mainly due to unrealized gains on preferred stock investments and stock warrants.
Successful Asset Sales and Fundraising
Sold a multifamily property for $60 million, resulting in a $3.7 million gain, and raised $65.7 million in gross proceeds from the Series B preferred stock raise.
Life Science Leasing Success
Secured a long-term lease with Lila Sciences for 245,000 square feet at the Alewife project, stabilizing the project and driving leasing momentum.